InterCure Announces the Withdrawal of a Class Action Lawsuit against it
06 December 2022 - 8:30AM
InterCure Ltd. (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba
Canndoc) ("
InterCure" or the
"
Company") is pleased to announce the withdrawal
of a class action lawsuit against it (the “Regenera Lawsuit”). The
Regenera Lawsuit was described in the Company’s press release dated
May 26, 2020 and in the Company's most recent Annual Report and
Annual Information Form and it was primarily concerning a motion to
certify, as a class action, a claim filed against the Company, its
directors and its executive officers, alleging that the Company
violated its obligation to publicly disclose certain events and
developments which impacted the valuation of Regenera Pharma Ltd.
(in which the Company held a 11.76% position during the time
relevant to the claim). On December 2, 2022, the Tel Aviv District
Court approved a consent motion to withdraw the Regenera Lawsuit,
without any payment to the plaintiff from the Company.
About InterCure (dba
Canndoc)InterCure (dba Canndoc) (NASDAQ: INCR) (TSX:
INCR.U) (TASE: INCR) is the leading, profitable, and fastest
growing cannabis company outside of North America. Canndoc, a
wholly owned subsidiary of InterCure, is Israel’s largest licensed
cannabis producer and one of the first to offer Good Manufacturing
Practices (GMP) certified and pharmaceutical-grade medical cannabis
products. InterCure leverages its market leading distribution
network, best in class international partnerships and a high-margin
vertically integrated "seed-to-sale" model to lead the fastest
growing cannabis global market outside of North America.
For more information, visit:
http://www.intercure.co.
Contact:
InterCure Ltd.Amos Cohen, Chief
Financial Officeramos@intercure.co
Intercure (TSX:INCR.U)
Historical Stock Chart
From May 2024 to Jul 2024
Intercure (TSX:INCR.U)
Historical Stock Chart
From Jul 2023 to Jul 2024